Q1 2021 Report: Scandion Oncology is evolving
Scandion Oncology A/S (”Scandion Oncology” or “the Company”) hereby publishes the Q1 2021 Report for the period January 1 – March 31, 2021. Bo Rode Hansen, President & CEO, Scandion Oncology A/S comments:“Scandion Oncology is evolving. Clinical progress and strengthening of the organization have marked the first quarter of 2021. With key hires in R&D, advisory roles, and business development we are building the organization with the competences needed to be ready for the upcoming milestones - the part 1 of the phase II CORIST study in Q2 2021, followed by a planned readout from the